Gene-editing nanodrug CTX310 shows promise in lowering 'bad' cholesterol with single injection
Quick Look
Two clinical trials in the US and China suggest a gene-editing nanodrug called CTX310 could provide long-term control of LDL cholesterol with a single injection by targeting the ANGPTL3 gene in liver cells, mimicking a natural mutation that reduces heart disease risk.
AI-generated summary
Why It Matters
High LDL cholesterol is a major risk factor for heart disease, the leading cause of death worldwide. Current treatment relies on daily statin pills for millions of people.
Imagine swapping your daily cholesterol pill for a single injection that keeps “bad” cholesterol under control for a year, a decade – or even a lifetime.
Two clinical trials, one in the United States and another in China, suggest that this one-and-done approach could become a reality.
Low-density lipoprotein cholesterol (LDL-C), better known as “bad” cholesterol, is a major driver of heart disease – the leading cause of death worldwide. Triglycerides, another type of blood fat, add to the risk.
For millions of people, the standard fix is a daily statin pill.
Research led by the Cleveland Clinic in the US and carried out in Australia, New Zealand and Britain, tested a gene-editing nanodrug called CTX310 on 15 volunteers.
The therapy uses tiny particles to carry a CRISPR gene-editing tool straight into liver cells. Its target is a gene named ANGPTL3, which helps control how much fat circulates in the blood.
Some people are born with a natural mutation that inhibits ANGPTL3. They have extremely low cholesterol and triglycerides, and they rarely develop heart disease.
CTX310 is designed to mimic that genetic switch.
Open Questions
- What were the specific results of the US and China clinical trials?
- How long does the effect of CTX310 last in humans?
- What are the potential side effects or risks of this gene-editing approach?
- When might CTX310 be available for public use?
